

Press Release

Lure (France), September 14, 2015


VÉTOQUINOL LAUNCHES UPCARD®, AN INNOVATIVE DRUG FOR CONGESTIVE HEART FAILURE IN DOGS

Vétoquinol continues the deployment of its reference products with the European launch of UPCARD[©], an innovative drug designed to treat congestive heart failure in dogs.

With the launch of UPCARD[©] in 2015, Vétoquinol brings to the market an innovative solution in the field of cardiology. UPCARD is the first ever torasemide-based diuretic registered for veterinary use and forms a valuable addition to Vétoquinol's existing animal cardiology range.

Cardiac diseases are common amongst dogs, currently affecting around 10% of canines, an increasing percentage in conjunction with the aging of the population. Most treatments are lifelong and must be administered several times a day, causing considerable inconvenience to pet owners.

The efficacy of UPCARD[©] treatment is rapidly visible: the once-a-day only administration makes it easier for pet owners to comply with the prescription. UPCARD improves the animal's quality of life and its life expectancy.



Vétoquinol CEO Matthieu Frechin explained: "The launch of UPCARD® is the culmination of a major development phase conducted by Vétoquinol. After the completion of a centralized procedure reserved for innovative medicines, Vétoquinol has obtained marketing authorization in all 28 European Union member states.

This new reference product is a valuable addition to our range and is fully in line with the implementation of our strategy."



Next update: Q3 2015 sales - October 22, 2015 after market close

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 2,024 people at June 30th, 2015. Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For further information, go to: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE

For any information, contact:

VETOQUINOL Investor Relations Marie-Josée Aubry-Rota Tel: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations Emmanuel Dovergne Tel: +33 (0)1 56 43 44 63

emmanuel.dovergne@keima.fr